Sidoti Forecasts Higher Earnings for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti upped their FY2026 earnings per share estimates for shares of USANA Health Sciences in a report issued on Thursday, February 19th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $2.00 for the year, up from their previous estimate of $1.84. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.66 EPS.

USNA has been the subject of several other reports. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $36.00.

USANA Health Sciences Stock Down 0.9%

Shares of USANA Health Sciences stock opened at $21.63 on Monday. The company has a market cap of $395.31 million, a P/E ratio of 39.32, a PEG ratio of 0.91 and a beta of 0.67. The firm’s 50 day moving average price is $20.76 and its 200-day moving average price is $23.35. USANA Health Sciences has a 52-week low of $18.48 and a 52-week high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19. The company had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in USNA. Pzena Investment Management LLC boosted its holdings in USANA Health Sciences by 1.2% in the third quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after purchasing an additional 14,328 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of USANA Health Sciences by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after buying an additional 21,793 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after buying an additional 57,249 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after buying an additional 17,318 shares during the period. Finally, Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences in the fourth quarter worth about $11,485,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling at USANA Health Sciences

In related news, insider Joshua Foukas sold 4,461 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $21.34, for a total value of $95,197.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.63% of the stock is owned by company insiders.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.